tert-butyl (4-aminopyridin-2-yl)carbamate | 1266119-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: tert-butyl (4-aminopyridin-2-yl)carbamate
• 英文别名: tert-butyl N-(4-aminopyridin-2-yl)carbamate
• CAS: 1266119-48-5
• 化学式: C₁₀H₁₅N₃O₂
• 分子量: 209.248
• InChiKey: VCKIIOUFGULFEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-aminopyridin-2-yl)carbamate 在 氢溴酸 、 乙酸酐 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 8.5h， 生成 1-(2-aminopyridin-4-yl)-6-chloro-7-[(2R)-2-({[3-chloro-6-(dimethylamino)pyridin-2-yl]oxy}methyl)-3-methylpyrrolidin-1-yl]-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  [EN] COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS
  [FR] COMPOSÉS CIBLANT DES PROTÉINES DE LIAISON À L'ARN OU DES PROTÉINES MODIFIANT L'ARN

  摘要：

  该发明涉及由化学式（I）表示的化合物，或其药用可接受盐，包括含有该化合物的组合物以及制备和使用该化合物的方法。这里描述了变量。

  公开号：

  WO2021178420A1
• 作为产物：
  描述：

  2-氨基-4-硝基吡啶 在 4-二甲氨基吡啶 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 生成 tert-butyl (4-aminopyridin-2-yl)carbamate
  参考文献：
  名称：

  [EN] BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS
  [FR] COMPOSÉS BIFONCTIONNELS ET LEUR UTILISATION POUR RÉDUIRE LES TAUX D'ACIDE URIQUE

  摘要：

  具有双重功能的化合物可以增加尿酸排泄并减少尿酸产生。提供了使用这些化合物来降低血液或血清中尿酸水平、治疗尿酸代谢紊乱疾病以及维持血液或血清中正常尿酸水平的方法。同时还提供了含有这些双功能化合物的药物组合物。

  公开号：

  WO2015123003A1

文献信息

• [EN] INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] DÉRIVÉS D'INDOLE ET DE BENZOXAZINE COMME MODULATEURS DES RÉCEPTEURS MÉTABOTROPIQUES AU GLUTAMATE
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010060589A1

  公开（公告）日：2010-06-03

  The present invention relates to novel indole and benzoxazine derivatives which are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2") and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及新型吲哚和苯并噁嗪衍生物，它们是代谢型谷氨酸受体亚型2（"mGluR2"）的正向变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病，以及涉及代谢型受体亚型mGluR2的疾病。该发明还涉及包含这些化合物的药物组合物，用于制备这些化合物和组合物的过程，以及利用这些化合物预防或治疗涉及mGluR2的神经和精神疾病和疾病。
• [EN] HETEROARYLAMINOISOQUINOLINES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF<br/>[FR] HÉTÉROARYLAMINOISOQUINOLINES, PROCÉDÉS POUR LES PRÉPARER ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：MINORYX THERAPEUTICS S L

  公开号：WO2016120808A1

  公开（公告）日：2016-08-04

  The application is directed to compounds of formula (IA) : and specifically compounds of formula (I) and their salts and solvates, wherein R1, R11, R12, R13, R4, R5, n, A1, A2, and A3 are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.

  该申请涉及式（IA）的化合物，特别涉及式（I）的化合物及其盐和溶剂合物，其中R1、R11、R12、R13、R4、R5、n、A1、A2和A3如规范中所述，以及它们的制备方法，包含它们的药物组合物，以及用于治疗和/或预防与β-半乳糖苷酶活性改变相关的病症的用途，特别是β-半乳糖苷酶1或GLB1，包括GM1神经节苷脂症和莫尔基奥综合征B型。
• INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Cid-Nunez Jose Maria

  公开号：US20120035167A1

  公开（公告）日：2012-02-09

  The present invention relates to novel indole and benzoxazine derivatives which are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及新型吲哚和苯并噁嗪衍生物，其为代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，并且对于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病具有用途。本发明还涉及包含这些化合物的制药组合物，制备这些化合物和组合物的过程以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病。
• IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Trabanco-Suarez Andres Avelino

  公开号：US20110009441A1

  公开（公告）日：2011-01-13

  The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是公式（I）中的新型咪唑并[1,2-a]吡啶衍生物。本发明的化合物是代谢型受体亚型2（“mGluR2”）的阳性变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病。特别是，这些疾病是来自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的群体。本发明还涉及制备这些化合物和组合物的制药组合物和制备过程，以及将这些化合物用于预防和治疗涉及mGluR2的这些疾病的用途。
• 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
  申请人：Wuxi Shuangliang Biotechnology Co., Ltd.

  公开号：EP3345906A1

  公开（公告）日：2018-07-11

  The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exonl9 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives.

  本公开涉及 2-芳基氨基吡啶、嘧啶或三嗪衍生物及其制备方法和用途。2-芳基氨基吡啶、嘧啶或三嗪衍生物可作用于表皮生长因子受体的某些突变形式，例如 L858R 激活突变体、delE746_A750 突变体、Exonl9 缺失激活突变体和 T790M 抗性突变体，从而可用于治疗和预防疾病和病症。2-芳基氨基吡啶、嘧啶或三嗪衍生物可用于治疗和预防癌症。本公开还涉及包含 2-芳基氨基吡啶、嘧啶或三嗪衍生物的药物组合物，用于制造 2-芳基氨基吡啶、嘧啶或三嗪衍生物的中间体，以及使用 2-芳基氨基吡啶、嘧啶或三嗪衍生物治疗由各种不同形式的表皮生长因子受体介导的疾病的方法。